The Hematology/Oncology Division at the University of Pennsylvania has been formally engaged in organizing the training of academic scientists since 1978. Throughout this time, the goal of the training program has been to help outstanding candidates with an interest in hematology related research to prepare themselves for academic careers in laboratory and/or clinical investigation. The record of success of this training program has been admirable. Of the 64 trainees who completed their program, 41 (64%) presently hold full-time appointments at some 21 institutions throughout the United States, and all of these 41 individuals are engaged in either laboratory (-33%) or clinical (-66%) research. Further, approximately half of our former trainees have extramural research funding, with direct costs in Fiscal year '98 exceeding $7 million. Based on this tradition of excellence and success, we now seek to establish an additional, more highly focused training program in the area of stem cell biology and hematopoiesis. The justification for establishing this specialized training program is based on a number of factors. First, there has been a significant expansion of laboratories interested in hematopoiesis and stem cell biology in the Division of Hematology/Oncology and in the wider University community as well. The increase in laboratories and faculty who share hematopoiesis as a primary focus has created an exciting environment which is attracting increasing numbers of post-doctoral and pre-doctoral students to the University. Therefore, the second reason to establish this training program is demand by potential trainees. Finally, the work being carried out in these laboratories is highly translational with great relevance to the field of gene therapy and the treatment of cancer. Therefore, regardless of the sub-area in which students elect to train, it is deemed quite likely that individuals who complete this program will be much in demand as a result of their ability to compete successfully for extramural funding and for the potential contributions they may make to the advancement of medical care.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Institutional National Research Service Award (T32)
Project #
5T32DK007780-08
Application #
7075386
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Bishop, Terry Rogers
Project Start
1999-09-20
Project End
2009-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
8
Fiscal Year
2006
Total Cost
$308,104
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Behera, Vivek; Evans, Perry; Face, Carolyne J et al. (2018) Exploiting genetic variation to uncover rules of transcription factor binding and chromatin accessibility. Nat Commun 9:782
Li, Ting; Wang, Wei; Gong, Shunyou et al. (2018) Genome-wide analysis reveals TNFAIP8L2 as an immune checkpoint regulator of inflammation and metabolism. Mol Immunol 99:154-162
Emptage, Ryan P; Lemmon, Mark A; Ferguson, Kathryn M et al. (2018) Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain. Structure 26:1137-1143.e3
Fang, Pu; Li, Xinyuan; Dai, Jin et al. (2018) Immune cell subset differentiation and tissue inflammation. J Hematol Oncol 11:97
Mowel, Walter K; Kotzin, Jonathan J; McCright, Sam J et al. (2018) Control of Immune Cell Homeostasis and Function by lncRNAs. Trends Immunol 39:55-69
Rech, Andrew J; Dada, Hannah; Kotzin, Jonathan J et al. (2018) Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. Cancer Res 78:4282-4291
Nelson, Caroline A; Noe, Megan H; McMahon, Christine M et al. (2018) Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol 78:303-309.e4
Yzaguirre, Amanda D; Howell, Elizabeth D; Li, Yan et al. (2018) Runx1 is sufficient for blood cell formation from non-hemogenic endothelial cells in vivo only during early embryogenesis. Development 145:
Yzaguirre, Amanda D; de Bruijn, Marella F T R; Speck, Nancy A (2017) The Role of Runx1 in Embryonic Blood Cell Formation. Adv Exp Med Biol 962:47-64
Babushok, Daria V; Duke, Jamie L; Xie, Hongbo M et al. (2017) Somatic HLA Mutations Expose the Role of Class I-Mediated Autoimmunity in Aplastic Anemia and its Clonal Complications. Blood Adv 1:1900-1910

Showing the most recent 10 out of 57 publications